期刊
TUMOR BIOLOGY
卷 35, 期 8, 页码 8259-8265出版社
SAGE PUBLICATIONS LTD
DOI: 10.1007/s13277-014-2072-0
关键词
ATP7B; Polymorphism; Lung cancer; Platinum; Chemotherapy; Efficacy
类别
资金
- National High-tech R&D Program of China (863 Program) [2012AA02A517]
- National Natural Science Foundation of China [81173129, 81202595, 81373490]
- Program for the Special Scientific Research Foundation of Doctor Disciplines in University of Ministry of Education of China [20110162110034]
- Hunan Provincial Natural Science Foundation of China [12JJ7006]
- Hunan Provincial Science and Technology Plan Projects [2011TT2025, 2012TT2021]
This study aims to investigate the influence of ATP7B genetic polymorphism to platinum-based chemotherapy in Chinese Han lung cancer patients. A total of 338 Chinese Han lung cancer patients were enrolled in this study. All patients underwent at least two cycles of platinum-based chemotherapy. Four tag SNPs of ATP7B (rs1061472, rs9535826, rs7999812, and rs9535828) were selected to evaluate their impacts to platinum-based chemotherapy in these patients. ATP7B rs9535828 and rs9535826 were found to be associated with platinum resistance in Chinese Han lung cancer patients. Patients with A allele in ATP7B rs9535828 presented an increased susceptibility to platinum drugs (OR 1.96, 95 % CI 1.17-3.30, p < 0.01). Patients with G allele in ATP7B rs9535826 had the highest susceptibility to platinum drugs (OR 2.05, 95 % CI 1.19-3.52, p < 0.01). Our findings suggest that ATP7B genetic polymorphisms could affect the therapeutic efficacy of platinum-based chemotherapy, and ATP7B gene might be considered as predictive markers for the efficacy evaluation of platinum-based chemotherapy in Chinese Han lung cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据